23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › FATE THERAPEUTICS INC. › 2023-2024

FATE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and FATE THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Reported items
  • 198Asset managers, any item
  • 1,771Fund votes
  • June 7, 2024Meeting date

Results at a glance

Meeting of June 7, 2024: 7 items on FATE THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 3 elected · 4 passed (calculated).

Dissent

Notable dissent: 1 say-on-pay vote (71.9% support); 2 other board items (36.8%, 34.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore FATE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by FATE THERAPEUTICS INC.

These tallies are FATE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

FATE THERAPEUTICS INC. — official shareholder meeting results, meeting held June 7, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: William H. Rastetter, Ph.D. 82,587,977---- 8,440,5277,162,328 91%Elected—
Elect Director: Michael Lee 90,262,212---- 1,188,4296,740,191 99%Elected—
Elect Director: Yuan Xi, Ph.D. 89,732,567---- 1,718,0746,740,191 98%Elected—
(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 96,478,449113,0031,599,380 ---- 99.9%Passed (calculated)—
(iii) Non-binding Advisory Vote on Compensation of Named Executive Officers. 65,401,63525,615,148433,964 --6,740,085 72%Passed (calculated)—
(v) Approval of the 2022 A&R Plan to increase the number of shares of common stock reserved for issuance thereunder. 59,762,46331,270,315417,969 --6,740,085 66%Passed (calculated)—
(vi) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals. 57,506,78933,547,222396,736 --6,740,085 63%Passed (calculated)—

This meeting is also recorded here as June 3, 2024; both records come from the same filing, so the date should be checked against it.

Source: FATE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the FATE THERAPEUTICS INC. 2023-2024 meeting

198 asset managers disclosed a vote on at least one FATE THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of FATE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Michael Lee

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 90,262,212WITHHELD: 1,188,429
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of Class II Directors: Michael Lee

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Lee”): 90,262,212 for, 1,188,429 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 26,563,963 for, 385,404 withheld.

FOR
FOR: 26,563,963WITHHOLD: 385,404
Largest asset managers voting on “Election of Class II Directors: Michael Lee” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,406,8610 00For
State Street5,966,0540 014,397For
Fidelity1,717,4380 0235,209Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust617,9510 00For
JPMorgan559,8570 00For
Victory Capital338,1220 00For
TIAA293,8830 00For
Dimensional278,5080 00For
Nationwide237,4240 00For
Equitable136,8900 0100,380Mixed
Columbia Threadneedle236,9480 00For
AIG/SunAmerica220,7440 00For
Goldman Sachs195,0100 00For
Brighthouse175,9220 00For
MFS161,3130 00For
T. Rowe Price157,9780 00For
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century135,4060 00For
ProShares120,8720 00For
Putnam118,2150 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: William H. Rastetter, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 82,587,977WITHHELD: 8,440,527
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of Class II Directors: William H. Rastetter, Ph.D.

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: William H. Rastetter, Ph.D.”): 82,587,977 for, 8,440,527 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 20,381,803 for, 6,567,564 withheld.

FORWITHHOLD
FOR: 20,381,803WITHHOLD: 6,567,564
Largest asset managers voting on “Election of Class II Directors: William H. Rastetter, Ph.D.” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,406,8610 00For
State Street127,8360 05,852,615Withhold
Fidelity1,717,4380 0235,209Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust617,9510 00For
JPMorgan559,8570 00For
Victory Capital338,1220 00For
TIAA293,8830 00For
Dimensional278,5080 00For
Nationwide237,4240 00For
Equitable136,8900 0100,380Mixed
Columbia Threadneedle00 0236,948Withhold
AIG/SunAmerica220,7440 00For
Goldman Sachs195,0100 00For
Brighthouse175,9220 00For
MFS161,3130 00For
T. Rowe Price157,9780 00For
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century135,4060 00For
ProShares120,8720 00For
Putnam118,2150 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Election of Class II Directors: Yuan Xu, Ph.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

97% of fund votes cast · no official result

FOR
Details: votes by 63 asset managers

The 63 asset managers below reported 26,259,453 for, 689,610 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 26,259,453WITHHOLD: 689,610
Largest asset managers voting on “Election of Class II Directors: Yuan Xu, Ph.D.” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,406,8610 00For
State Street5,966,0540 014,397For
Fidelity1,717,4380 0235,209Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust617,9510 00For
JPMorgan559,8570 00For
Victory Capital338,1220 00For
TIAA293,8830 00For
Dimensional00 0278,508Withhold
Nationwide237,4240 00For
Equitable136,8900 0100,380Mixed
Columbia Threadneedle236,9480 00For
AIG/SunAmerica220,7440 00For
Goldman Sachs195,0100 00For
Brighthouse175,9220 00For
MFS161,3130 00For
T. Rowe Price157,9780 00For
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century135,4060 00For
ProShares120,8720 00For
Putnam118,2150 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer…

No official matchCORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 64 asset managers

Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law.

The 64 asset managers below reported 26,036,836 for, 877,113 against, 35,418 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 26,036,836AGAINST: 877,113ABSTAIN: 35,418
Largest asset managers voting on “To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an offic” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,406,8610 00For
State Street5,970,11710,334 00For
Fidelity1,952,6470 00For
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust617,9510 00For
JPMorgan0559,857 00Against
Victory Capital338,1220 00For
TIAA293,8830 00For
Dimensional278,5080 00For
Nationwide236,1091,315 00For
Equitable237,2700 00For
Columbia Threadneedle236,9480 00For
AIG/SunAmerica220,7440 00For
Goldman Sachs195,0100 00For
Brighthouse18,491157,431 00Mixed
MFS161,3130 00For
T. Rowe Price157,9780 00For
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century135,4060 00For
ProShares120,8720 00For
Putnam118,2150 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

(vi) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 2 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%AGAINST
FOR: 57,506,789AGAINST: 33,547,222
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.

FATE THERAPEUTICS INC.’s own tally for this item (“(vi) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.”): 57,506,789 for, 33,547,222 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 16,392,183 for, 10,521,766 against, 35,418 abstained.

FORAGAINST
FOR: 16,392,183AGAINST: 10,521,766ABSTAIN: 35,418
Largest asset managers voting on “To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meet” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,355,86151,000 00For
State Street65,0535,915,398 00Against
Fidelity1,693,538259,109 00Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco0800,607 00Against
Direxion Shares ETF Trust0617,951 00Against
JPMorgan559,8570 00For
Victory Capital0338,122 00Against
TIAA0293,883 00Against
Dimensional0278,508 00Against
Nationwide0237,424 00Against
Equitable232,4704,800 00For
Columbia Threadneedle0236,948 00Against
AIG/SunAmerica0220,744 00Against
Goldman Sachs0195,010 00Against
Brighthouse157,43118,491 00Mixed
MFS0161,313 00Against
T. Rowe Price0157,978 00Against
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century0135,406 00Against
ProShares0120,872 00Against
Putnam118,2150 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

(v) Approval of the 2022 A&R Plan to increase the number of shares of common stock reserved for issuance thereunder.

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 3 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%AGAINST
FOR: 59,762,463AGAINST: 31,270,315
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: To approve the amendment and restatement of the Company's 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.

FATE THERAPEUTICS INC.’s own tally for this item (“(v) Approval of the 2022 A&R Plan to increase the number of shares of common stock reserved for issuance thereunder.”): 59,762,463 for, 31,270,315 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 16,763,054 for, 10,107,654 against, 78,817 abstained.

FORAGAINST
FOR: 16,763,054AGAINST: 10,107,654ABSTAIN: 78,817
Largest asset managers voting on “To approve the amendment and restatement of the Company's 2022 Stock Option and Incentive Plan to increase the” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,355,86151,000 00For
State Street65,0535,915,398 00Against
Fidelity1,693,538259,109 00Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust0617,951 00Against
JPMorgan0559,857 00Against
Victory Capital0338,122 00Against
TIAA293,8830 00For
Dimensional0278,508 00Against
Nationwide1,315236,109 00Against
Equitable232,4704,800 00For
Columbia Threadneedle0236,948 00Against
AIG/SunAmerica0220,744 00Against
Goldman Sachs0195,010 00Against
Brighthouse0175,922 00Against
MFS0161,313 00Against
T. Rowe Price0157,978 00Against
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century0135,406 00Against
ProShares0120,872 00Against
Putnam0118,215 00Against

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

(iii) Non-binding Advisory Vote on Compensation of Named Executive Officers.

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST
FOR: 65,401,635AGAINST: 25,615,148

Prior year: 96.2% for (June 6, 2023 meeting) ▼ 24.3 pts

Details: description as filed, official tally, votes by 194 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

FATE THERAPEUTICS INC.’s own tally for this item (“(iii) Non-binding Advisory Vote on Compensation of Named Executive Officers.”): 65,401,635 for, 25,615,148 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of FATE THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, 13,341 for, 3,451,652 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 64 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,355,86151,000 00For
State Street5,892,93787,514 00For
Fidelity1,693,538259,109 00Mixed
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco0800,607 00Against
Direxion Shares ETF Trust0617,951 00Against
JPMorgan0559,857 00Against
Victory Capital0338,122 00Against
TIAA0293,883 00Against
Dimensional0278,508 00Against
Nationwide1,315236,109 00Against
Equitable132,090105,180 00Mixed
Columbia Threadneedle236,9480 00For
AIG/SunAmerica0220,744 00Against
Goldman Sachs0195,010 00Against
Brighthouse0175,922 00Against
MFS0161,313 00Against
T. Rowe Price0157,978 00Against
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century0135,406 00Against
ProShares0120,872 00Against
Putnam118,2150 00For

Fund voting reports, all 64 managers: 21,860,580 for, 5,009,970 against, 78,817 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 154 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC13,169,0570 00For
State Street7,012,73597,718 00For
Deep Track Capital, LP5,331,5780 00For
Bellevue Group AG04,839,779 00Against
BlackRock3,701,35531,116 00For
Johnson & Johnson Innovation - JJDC, Inc.3,379,0640 00For
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)3,098,5000 00For
DE Shaw02,261,602 00Against
GEODE CAPITAL MANAGEMENT, LLC1,805,3060 00For
Woodline Partners LP1,726,6860 00For
Citadel1,687,7570 00For
ORBIMED ADVISORS LLC1,301,1620 00For
JACOBS LEVY EQUITY MANAGEMENT, INC01,201,667 00Against
Two Sigma01,186,681 00Against
Point7201,107,330 00Against
Holocene Advisors, LP01,075,781 00Against
Federated Hermes975,4730 00For
Charles Schwab960,8860 00For
Invesco0827,152 00Against
Vestal Point Capital, LP0800,000 00Against
ACADIAN ASSET MANAGEMENT LLC0665,307 00Against
Rafferty Asset Management, LLC0617,951 00Against
JPMorgan0450,848 00Against
Northern Trust413,5824,764 00For
Vanguard390,4500 00For

Institutional-manager reports, all 154 managers: 46,606,245 for, 18,541,610 against, 316,220 abstained, 3,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 96,478,449AGAINST: 113,003

Prior year: 99.8% for (June 6, 2023 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

FATE THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 96,478,449 for, 113,003 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 26,903,311 for, 10,638 against, 35,418 abstained.

FOR
FOR: 26,903,311AGAINST: 10,638ABSTAIN: 35,418
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Com” at FATE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,406,8610 00For
State Street5,970,11710,334 00For
Fidelity1,952,6470 00For
BlackRock1,739,6870 00For
Federated Hermes969,5140 00For
Charles Schwab960,8860 00For
Invesco800,6070 00For
Direxion Shares ETF Trust617,9510 00For
JPMorgan559,8570 00For
Victory Capital338,1220 00For
TIAA293,8830 00For
Dimensional278,5080 00For
Nationwide237,4240 00For
Equitable237,2700 00For
Columbia Threadneedle236,9480 00For
AIG/SunAmerica220,7440 00For
Goldman Sachs195,0100 00For
Brighthouse175,9220 00For
MFS161,3130 00For
T. Rowe Price157,9780 00For
QUANTITATIVE MASTER SERIES LLC157,9730 00For
BRUCE FUND INC143,0000 00For
American Century135,4060 00For
ProShares120,8720 00For
Putnam118,2150 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest FATE THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 113,798,942 shares outstanding at the time of that meeting.

Fund voting reports: top FATE THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers as…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.27%
2State Street 5.26%
3Fidelity 1.72%
4BlackRock 1.53%
5Federated Hermes 0.85%
6Charles Schwab 0.84%
7Invesco 0.70%
8Direxion Shares ETF Trust 0.54%
9JPMorgan 0.49%
10Victory Capital 0.30%
Institutional-manager reports: top FATE THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers as…”, 2023-2024
#Asset manager % of shares outstanding
1Redmile Group, LLC 11.57%
2State Street 6.25%
3Deep Track Capital, LP 4.69%
4Bellevue Group AG 4.25%
5BlackRock 3.28%
6Johnson & Johnson Innovation - JJDC, Inc. 2.97%
7DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2.72%
8DE Shaw 1.99%
9GEODE CAPITAL MANAGEMENT, LLC 1.59%
10Woodline Partners LP 1.52%

Reported FATE THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

FATE THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Redmile Group, LLC13,169,057 11.57%Proxy statement (DEF 14A), proxy filed April 26, 2024
BlackRock10,680,727 9.39%Form 13F, quarter ended March 31, 2024
ARK Investment Management LLC10,312,167 9.06%Proxy statement (DEF 14A), proxy filed April 26, 2024
Vanguard Group8,798,491 7.73%Form 13F, quarter ended March 31, 2024
State Street8,036,669 7.06%Form 13F, quarter ended March 31, 2024
Boxer Capital, LLC6,171,000 5.42%Proxy statement (DEF 14A), proxy filed April 26, 2024
Citadel Advisors3,154,626 2.77%Form 13F, quarter ended March 31, 2024
D.E. Shaw2,730,966 2.40%Form 13F, quarter ended March 31, 2024
Geode Capital1,905,983 1.67%Form 13F, quarter ended March 31, 2024
Point721,584,300 1.39%Form 13F, quarter ended March 31, 2024

Percentages above are of 113,798,942 shares outstanding, as reported by FATE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At FATE THERAPEUTICS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 198 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,771 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — FOR was 72% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: FATE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from FATE THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

FATE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “FATE THERAPEUTICS (FATE) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/fate-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.